Edit
Atlas Genetics
http://atlasgenetics.com/Last activity: 23.01.2017
Active - Reference to binx health
Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-patient and Point-of-Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-to-use, rapid and cost-effective solution for on-demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases.
Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund.
Atlas Genetics is a global company and has locations in Boston, MA and Bath UK.
For further information visit www.atlasgenetics.com.
Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund.
Atlas Genetics is a global company and has locations in Boston, MA and Bath UK.
For further information visit www.atlasgenetics.com.
Location: United States, Massachusetts, Boston
Employees: 11-50
Phone: +1 217-714-6020
Total raised: $110.71M
Founded date: 2005
Investors 1
| Date | Name | Website |
| - | Life Scien... | lspvc.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 23.01.2017 | Series D | $35M | - |
| 29.01.2015 | Series C | $20M | - |
| 29.04.2014 | Series B | $28.43M | - |
| 20.07.2011 | Series B | $27.28M | - |
Mentions in press and media 9
| Date | Title | Description |
| 23.01.2017 | Atlas Genetics Raises $35M in Series D Funding | Atlas Genetics Ltd., a Bath, England, UK-based ultra-rapid Point-Of-Care (POC) molecular diagnostics company, closed $35m in Series D financing. Backers included existing investors Novartis Venture Funds, Consort Medical plc, Johnson & ... |
| 29.01.2015 | Atlas Genetics Raises $20M in Series C Funding | Atlas Genetics, a Trowbridge, UK-based developer of diagnostic tests for infectious diseases, raised $20m in Series C funding. Backers included new investor RMI Partners and existing investors Novartis Venture Funds, Consort Medical plc, Jo... |
| 29.01.2015 | British diagnostics startup Atlas Genetics will use $20M Series C to start U.S. clinical trials for STI testing | “This will enable clinicians to test and commence treatment within the same appointment and ensure much improved compliance, particularly in the area of STIs, where a significant proportion of patients fail to return for test results or fol... |
| 29.04.2014 | Atlas Genetics Raised £16.9M in Series B Funding | Atlas Genetics, a Bath, UK-based diagnostic company that provides tests for infectious diseases, raised £16.9m in Series B funding. Backers included Novartis Venture Funds, Consort Medical plc, Life Sciences Partners, BB Biotech Ventures, J... |
| 16.01.2014 | TTP and Atlas Genetics development partnership creates ultra-rapid point-of-care instrument | TTP and Atlas Genetics development partnership creates ultra-rapid point-of-care instrument 16-01-2014 TTP is delighted to announce that it has completed development of the Atlas io™ Reader instrument for Atlas Genetics. The Atlas io™ syste... |
| 20.07.2011 | Atlas Genetics Raises £16.9M in Series B Funding | Atlas Genetics Ltd, a Bristol, UK-based diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases, has raised £16.9m in Series B funding. Investors include Novartis Venture Funds, and Consort Medical, ... |
| 18.07.2011 | Atlas Genetics Ltd Completes £16.9 million Series B Financing led by Novartis Venture Funds | - |
| 13.02.2008 | Life sciences briefing: Wednesday, Feb. 13, 2008 | TODAY’S HEADLINES: Molecular-diagnostics maker Atlas Genetics gets £2.1M (MS Word release) One-man shop Paloma Pharma takes in $5M for eye, cancer drugs (VentureWire) Israel’s Optimata receives $1.5M for simulations to rescue failed drugs (... |
| - | British diagnostics startup Atlas Genetics will use $20M Series C to start U.S. clinical trials for STI testing | Atlas Genetics, a British molecular diagnostics startup that creates rapid point-of-care tests for infectious diseases like chlamydia, will launch U.S. clinical trials with a $20 million Series C round. It will also expand its test offering... |